AI drug-discovery startup Boltz raises $110 million in a Series A funding round, aimed at accelerating small-molecule research. SiliconANGLE reports the round is led by Bessemer and says a consortium includes both new and returning backers, naming Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital and Hummingbird among others. Tech.eu similarly describes Boltz as a London-based AI drug discovery company that develops AI models for drug development.
Tech.eu adds that the company emerged from stealth less than a year ago, placing the investment in the context of a rapid early-stage timeline. Across the coverage, the shared focus is Boltz’s use of AI to help pharmaceutical researchers move faster, with differences mainly in the emphasis on round leadership and the specific list of participating investors. Neither source describes regulatory approvals, partnerships, or concrete research milestones tied to the funding in the excerpts provided.